Targeting TGF‐β signaling in Liver Cancer

Abstract

Hepatocellular carcinoma (HCC), accounting for 85‐90% of all primary liver cancers, is among the most prevalent and lethal cancers in the world, with five‐year survival for advanced cases under 11%. Ineffective detection of tumors and drug resistance are some of the causal factors for therapy failure. Thus, there is an urgent need to understand the molecular mechanisms underlying drug resistance and HCC initiation. Development of HCC is associated with alterations in the TGF‐β signaling pathway which plays a critical role in cell proliferation, apoptosis, differentiation, motility, lineage specificity, as well as normal stem cell homeostasis.

This article is protected by copyright. All rights reserved.

https://ift.tt/2Lj29nD